academic article

• Athauda AFong CLau DKJavle MAbou-Alfa GKMorizane CSteward KChau I. Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation.  Cancer Treatment Reviews.  86. 2020
  Full text if available
• Lau DKWKalaitzaki EChurch DNPandha HTomlinson IAnnels NGerlinger MSclafani FSmith GBegum RCrux RGillbanks AWordsworth SChau IStarling NCunningham DDhillon T. Rationale and design of the POLEM trial: Avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: A phase III randomised study.  ESMO Open.  5:1-6. 2020
  Full text if available
• Lau DKBurge MRoy AChau IHaller DGShapiro JDPeeters MPavlakis NKarapetis CSTebbutt NCSegelov EPrice TJ. Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019.  Expert Review of Anticancer Therapy: an essential contribution to decision making in cancer care.  20:251-270. 2020
  Full text if available
• Lau DKMouradov DWasenang WLuk IYScott CMWilliams DSYeung YHLimpaiboon TIatropoulos GFJenkins LJReehorst CMChionh FNikfarjam MCroagh DDhillon ASWeickhardt AJMuramatsu TSaito YTebbutt NCSieber OMMariadason JM. Genomic profiling of biliary tract cancer cell lines reveals molecular subtypes and actionable drug targets.  iScience.  21:624-637. 2019
  Full text if available
• Lau DKTay RYYeung YHChionh FMooi JMurone CSkrinos EPrice TJMariadason JMTebbutt NC. Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study.  British Journal of Cancer.  118:966-971. 2018
  Full text if available
• Yeung YLau DKChionh FTran HTse JWTWeickhardt AJNikfarjam MScott AMTebbutt NCMariadason JM. K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.  Molecular Oncology.  11:1130-1142. 2017
  Full text if available
• Chionh FLau DYeung YPrice TTebbutt N. Oral versus intravenous fluoropyrimidines for colorectal cancer.  Cochrane Database of Systematic Reviews.  2017:1-218. 2017
  Full text if available
• Parakh SMurphy CLau DCebon JSAndrews MC. Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.  Journal of Clinical Pharmacy and Therapeutics.  40:121-123. 2015
  Full text if available
• Lau DKAndrews MCTurner NAzad AADavis IDCebon JS. A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme.  Melanoma Research: an international journal of rapid communications of basic and clinical research in melanoma.  24:144-149. 2014
  Full text if available